Literature DB >> 24355642

Pulmonary arterial hypertension: epidemiology and registries.

Michael D McGoon1, Raymond L Benza2, Pilar Escribano-Subias3, Xin Jiang4, Dave P Miller5, Andrew J Peacock6, Joanna Pepke-Zaba7, Tomas Pulido8, Stuart Rich9, Stephan Rosenkranz10, Samy Suissa11, Marc Humbert12.   

Abstract

Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in characterizing the presentation and natural history of the disease and provide a basis for prognostication. Since the initial accumulation of data conducted in the 1980s, subsequent registry databases have yielded information about the demographic factors, treatment, and survival of patients and have permitted comparisons between populations in different eras and environments. Inclusion of patients with all subtypes of PAH has also allowed comparisons of these subpopulations. We describe herein the basic methodology by which PAH registries have been conducted, review key insights provided by registries, summarize issues related to interpretation and comparison of the results, and discuss the utility of data to predict survival outcomes. Potential sources of bias, particularly related to the inclusion of incident and/or prevalent patients and missing data, are addressed. A fundamental observation of current registries is that survival in the modern treatment era has improved compared with that observed previously and that outcomes among PAH subpopulations vary substantially. Continuing systematic clinical surveillance of PAH will be important as treatment evolves and as understanding of mechanisms advance. Considerations for future directions of registry studies include enrollment of a broader population of patients with pulmonary hypertension of all clinical types and severity and continued globalization and collaboration of registry databases.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-min walk distance; 6MWD; CRF; CTEPH; NIH; National Institutes of Health; PAH; PH; PPH; case report form; chronic thromboembolic pulmonary hypertension; databases; epidemiology; primary pulmonary hypertension; pulmonary arterial hypertension; pulmonary hypertension; registries

Mesh:

Year:  2013        PMID: 24355642     DOI: 10.1016/j.jacc.2013.10.023

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  149 in total

Review 1.  Definition, epidemiology and registries of pulmonary hypertension.

Authors:  R Awdish; H Cajigas
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension.

Authors:  Mei-Sing Ong; Mary P Mullen; Eric D Austin; Peter Szolovits; Marc D Natter; Alon Geva; Tianxi Cai; Sek Won Kong; Kenneth D Mandl
Journal:  Circ Res       Date:  2017-06-13       Impact factor: 17.367

3.  Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Authors:  Kirsty M Mair; Audrey F Wright; Nicholas Duggan; David J Rowlands; Martin J Hussey; Sonia Roberts; Josephine Fullerton; Margaret Nilsen; Lynn Loughlin; Matthew Thomas; Margaret R MacLean
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

4.  Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan.

Authors:  Le-Yung Wang; Kuang-Tso Lee; Chia-Pin Lin; Lung-An Hsu; Chun-Li Wang; Tsu-Shiu Hsu; Wan-Jing Ho
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 5.  Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.

Authors:  Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2014-12-06       Impact factor: 5.460

6.  Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Diana Khaybullina; Ami Patel; Tina Zerilli
Journal:  P T       Date:  2014-11

7.  Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension.

Authors:  A Zimmer; R B Teixeira; J H P Bonetto; R Siqueira; C C Carraro; L M Donatti; A Hickmann; I E Litvin; A E G Godoy; A S Araujo; R Colombo; Adriane Belló-Klein
Journal:  Mol Cell Biochem       Date:  2017-02-08       Impact factor: 3.396

Review 8.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

9.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

Review 10.  World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Authors:  Kurt W Prins; Thenappan Thenappan
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.